Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results

SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced its financial results for the quarter ended June 30, 2011.


Optimer reported net loss for the second quarter of 2011 of $24.2 million, or ($0.52) per share on both a basic and diluted basis, as compared to a net loss for the second quarter of 2010 of $10.1 million, or ($0.26) per share on both a basic and diluted basis.  The increase in net loss was primarily due to increases in marketing, research and development, and general and administrative expenses related to the U.S. approval and third quarter launch of DIFICID™.

Marketing expenses for the second quarter of 2011 increased $6.3 million compared to the second quarter of 2010 due to Optimer's efforts to establish a commercial infrastructure and prepare for the launch of DIFICID, including the hiring of approximately 100 marketing and sales staff.  General and administrative expenses increased $3.8 million compared to the second quarter of 2010, primarily because of higher compensation expense due to additional headcount as well as higher recruitment, consulting, facilities and legal expenses.  Research and development expenses increased $4.2 million compared to the second quarter of 2010 due to higher health economics research, pharmacovigilance, medical affairs  and publication expenses, as well as higher research and development expenses by OBI associated with the OPT-822 Phase 2/3 trial in breast cancer.

As of June 30, 2011, Optimer held cash, cash equivalents and short-term investments of $157.8 million and had 46,602,501 shares outstanding.

"The second quarter culminated with the FDA approval of DIFICID for the treatment of C. difficile-associated diarrhea, or CDAD, in patients over the age of 18, which includes clear differentiation and superiority over oral vancomycin in sustained clinical response 25 days after the end of therapy," said Pedro Lichtinger, President and CEO of Optimer.  "Our success with the FDA approval and the recent launch of DIFICID can be attributed to thorough preparation and execution by our team. We remain highly focused on the successful introduction of DIFICID to physicians and patients, and on establishing DIFICID, based on the clinical experience to date, as the preferred treatment for CDAD patients."

Second Quarter and Recent Highlights

  • On May 27, the U.S. Food and Drug Administration approved Optimer's antibacterial drug DIFICID™ (fidaxomicin) Tablets for the treatment of CDAD in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease.
  • On July 18, Optimer announced the commercial launch of DIFICID™ Tablets for the treatment of CDAD in patients 18 years of age and older.
  • Optimer entered into a co-promotion agreement with Cubist Pharmaceuticals to market DIFICID for the treatment of CDAD in the U.S. to help maximize the impact of, and de-risk, the commercial launch of DIFICID.
  • Optimer also presented additional data analysis from the DIFICID Phase 3 clinical trials highlighting risk factors associated with negative outcomes in patients with CDAD such as advanced age and immunosuppression. Data were presented at key scientific conferences including the European Congress of Clinical Microbiology and Infectious Diseases, Digestive Disease Week and the Annual Meeting of the American Geriatric Society.

  • About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at

    Forward Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation statements related to Optimer's plans to commercialize DIFICID, including with its co-promotion partner, the incidence of CDAD, and Optimer's expectations regarding the impact of the commercial launch of DIFICID. Words such as "believes", "would", "anticipates", "plans", "expects", "may", "intend", "will", and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the implementation and continuation of Optimer's co-promotion agreement with Cubist, Optimer's and Cubist's ability to commercialize DIFICID according to Optimer's expected scope and timelines, the ability of Optimer and its third party contractors to manufacture and supply sufficient quantities of DIFICID in accordance with Good Manufacturing Practices to meet demand, whether healthcare professionals will prescribe DIFICID, whether DIFICID will receive reimbursement coverage from healthcare payors and government agencies, the extent to which DIFICID will be accepted on hospital formularies, Optimer's ability to successfully manage a sales and marketing organization and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    Optimer Pharmaceuticals, Inc.
    David Walsey, Vice President, Investor Relations and Corporate Communications

    Canale Communications, Inc.
    Jason I. Spark, Senior Vice President
    619-849-6005Optimer Pharmaceuticals, Inc.Consolidated Statements of Operations(unaudited) Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, 2011201020112010Revenues:Licensing

    - $
    - $69,165,000 $
    - Research grants

    33,294357,436144,933654,873   Total revenues

    33,294357,43669,309,933654,873Cost and expenses:   Cost of licensing

    --4,273,532-Research and development


    6,974,322656,46410,407,915925,058General and administrative

    7,506,5253,686,44215,786,7076,075,154Total operating expenses

    25,051,48310,762,15749,509,29924,781,042Income (loss) from operations

    (25,018,189)(10,404,721)19,800,634(24,126,169)Interest income and other, net

    95,86053,719119,10278,497Consolidated net income (loss)

    $ (24,922,329)$  (10,351,002)$19,919,736$(24,047,672)Net loss attributable to noncontrolling interest

    683,483290,105974,288491,020Net income (loss) attributable to Optimer Pharmaceuticals, Inc.

    $ (24,238,846)$  (10,060,897)$20,894,024$(23,556,652)Net income (loss) per share - basic

    (0.64)Net income (loss) per share - diluted

    (0.64)Weighted average number of shares used to compute net  income (loss) per share - basic

    46,479,39538,306,91044,581,01036,663,380Weighted average number of shares used to compute net  income (loss) per share - diluted

    46,479,39538,306,91045,447,26136,663,380Optimer Pharmaceuticals, Inc.Condensed Consolidated Balance SheetsJune 30December 31,20112010(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $   61,402,529$   19,861,924Short-term investments

    96,391,74229,553,506Research grant and other  receivables


    1,369,482-Prepaid expenses and other current assets

    5,843,511463,307Total current assets

    165,086,22149,932,289Property and equipment, net

    2,172,443697,683Long-term investments

    882,000882,000Other assets

    1,242,523508,190Total assets

    $ 169,383,187$   52,020,162LIABILITIES  AND STOCKHOLDERS' EQUITY Current liabilities:Accounts payable

    2,307,820Accrued expenses

    5,080,6792,385,046Total current liabilities

    11,819,1714,692,866Deferred rent

    183,515141,138Stockholders’ equity

    157,380,50147,186,158Total liabilities and stockholders’ equity

    $ 169,383,187$   52,020,162

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
    2. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
    4. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
    5. Optimer Pharmaceuticals Expands Senior Management Team
    6. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
    7. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
    8. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
    9. Trading Halted Today in Optimer Pharmaceuticals Stock
    10. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
    11. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
    Post Your Comments:
    (Date:10/8/2015)... 8, 2015  Ardelyx, Inc. (NASDAQ: ARDX ... and cardio-renal diseases, today announced that clinical data ... be presented at the 2015 American College of ... measures of sustained response in IBS-C patients enrolled ... Phase 2 trial. The meeting will be held ...
    (Date:10/8/2015)... 2015  Allergan plc (NYSE: AGN ), a ... hold its R&D Day on November 4, from 11:00 ... 1:00 p.m. PT). The company will also host its ... a.m. ET (6:00 a.m. PT). ... --> Logo - ...
    (Date:10/8/2015)... , Oct. 8, 2015  The National ... approximately $40 million to the Broad Institute of ... sequencing of 20,000 individuals, as well as data ... metabolite profiling. Trans-Omics for Precision Medicine ... step toward a larger initiative, which will use ...
    Breaking Medicine Technology:
    ... MELVILLE, N.Y., April 23, 2012  Henry Schein, ... provider of health care products and services to dental, ... with the launch of its 2012 Global Reflections program ... "Henry Schein firmly believes that protecting ...
    ... Systems, Inc. (NASDAQ: DCTH ) today announced it ... revolver with Silicon Valley Bank ("SVB"), a leading provider of ... available for general corporate purposes supporting the overall growth and ... transaction, Eamonn P. Hobbs, President & CEO of Delcath Systems, ...
    Cached Medicine Technology:
    (Date:10/9/2015)... Francisco, CA (PRWEB) , ... October 09, 2015 ... ... Geneva, Switzerland for highly sought after internships at the pre-eminent organization in global ... movement dedicated to eliminating social and health disparities. These internships are a mechanism ...
    (Date:10/9/2015)... ... ... "My spouse and I rely on canes to walk, and we both have ... Buffalo, N.Y. "This is not only frustrating but it’s unsanitary. My design solves this ... to keep a cane upright while it’s not in use. It prevents the cane ...
    (Date:10/9/2015)... ... ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend the USA ... Huntsville, Texas on October 17-21. , "It's very exciting to be invited to ... director, said. “It's a stepping stone into the U.S. elite system where Maddie and ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Confidence Plus Insurance ... a community improvement initiative that involves working with a series of local charities ... of Confidence Plus Insurance is the Gleason Park Electric Violin Ensemble (GPEVE). , ...
    (Date:10/9/2015)... ... October 09, 2015 , ... MMJ PhytoTech Limited ... Ed Begley Jr., airing 1st QT 2016 via the Discovery Channel. Dates and ... Phytotech Limited (MMJ) – a global leader in the field of commercializing medicinal ...
    Breaking Medicine News(10 mins):
    ... News) -- Crohn,s disease may cause post-traumatic stress disorder ... nearly 600 Swiss adults with Crohn,s disease, an incurable ... The study participants underwent PTSD assessment at the ... were found to have the disorder. All the participants ...
    ... News) -- A U.S. Food and Drug Administration advisory committee ... prevention of prostate cancer, the third-highest cancer killer of men. ... the risks of Merck,s Proscar outweighed its benefits, according to ... the panel voted 14-2, with two abstentions, against GlaxoSmithKline,s Avodart. ...
    ... veterans are nearly three times as likely as civilians ... researchers at Portland State University (PSU) and Oregon Health ... Deaths Among Women With U.S. Military Service: A Hidden ... Psychiatric Services , a journal published by the American ...
    ... HealthDay Reporter , WEDNESDAY, Dec. 1 (HealthDay News) -- The ... from CT scans may be lower than previously thought, new ... Wednesday at the annual meeting of the Radiological Society of ... of Medicare records covering nearly 11 million patients. , "What ...
    ... , WEDNESDAY, Dec. 1 (HealthDay News) -- The case of ... colitis -- and actually got better -- sheds light on ... study suggests. "Our findings in this case report suggest ... roundworm can alleviate the symptoms of ulcerative colitis," said ...
    ... Medicine (BUSM) have identified a mechanism by which specific viruses ... This finding, which is currently featured in an online edition ... to the development of more targeted treatments against many types ... Dunn, a postdoctoral fellow, under the direction of John H. ...
    Cached Medicine News:
    ... Tri-Flo® suction catheter design was created ... patients while still providing high suctioning ... (5/6, 8 or 10 Fr) feature ... catheter placement. Our complete catheter line ...
    Tracheal Suction Latex Rubber Catheters - Funnel End...
    Rubber bronchial coude catheter, X-ray opaque, one eye, whistle tip....
    KCIs KinAir IV combines Advanced Pressure Relief Therapy with a manual wound care turn to provide optimum skin care and patient,positioning....
    Medicine Products: